The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups

International Journal of Infectious Diseases

Volumn 13, Issue 1, 2009, Pages 24-36

  Tong, Kuo B ^a   Lau, Christopher J ^a   Murtagh, Kirsten ^a   Layton, Andrew J ^a   Seifeldin, Raafat ^b  

^a Quorum Consulting Inc   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Aspergillosis; Hospital costs; MedPAR

Indexed keywords

ADULT; AGED; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; COMORBIDITY; CONTROLLED STUDY; ECONOMIC ASPECT; FEMALE; FINANCIAL MANAGEMENT; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITAL RUNNING COST; HUMAN; INFECTION RATE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; REIMBURSEMENT; UNITED STATES;

ADOLESCENT; ADULT; AGED; ASPERGILLOSIS; DIAGNOSIS-RELATED GROUPS; FEMALE; HEALTH CARE COSTS; HOSPITAL CHARGES; HOSPITAL COSTS; HUMANS; INCIDENCE; INSURANCE, HEALTH, REIMBURSEMENT; LENGTH OF STAY; MALE; MEDICARE; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

EID: 57849148517     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2008.02.013     Document Type: Article

References (26)

1. Stevens D.A., Kan V.L., Judson M.A., Morrison V.A., Dummer S., Denning D.W., et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 30 (2003) 696-709
2. Soubani A.O., and Chandrasekar P.H. The clinical spectrum of pulmonary aspergillosis. Chest 121 (2002) 1988-1999
3. Lin S., Schranz J., and Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32 (2003) 358-366
4. Singh N. The current management of infectious diseases in the liver transplant recipient. Clin Liver Dis 4 (2000) 657-673 ix
5. Morgan J., Wannemuehler K.A., Marr K.A., Hadley S., Kontoyiannis D.P., Walsh T.J., et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 43 Suppl 1 (2005) S49-S58
6. Groll A.H., Shah P.M., Mentzel C., Schneider M., Just-Nuebling G., and Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33 (1996) 23-32
7. Warnock D.W. Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi 48 (2007) 1-12
8. Denning D.W. Invasive aspergillosis. Clin Infect Dis 26 (1998) 781-805
9. Van Gool R. The cost of treating systemic fungal infections. Drugs 61 Suppl 1 (2001) 49-56
10. Marr K.A., Carter R.A., Crippa F., Wald A., and Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34 (2002) 909-917
11. Marr K.A., Seidel K., Slavin M.A., Bowden R.A., Schoch H.G., Flowers M.D., et al. Prolonged fluconazole prophylaxis increases long term survival and protects against candidiasis deaths for allogeneic marrow transplants. Evidence-based Oncology 2 (2001) 17-18
12. Wingard J.R. Antifungal chemoprophylaxis after blood and marrow transplantation. Clin Infect Dis 34 (2002) 1386-1390
13. Wilson L.S., Reyes C.M., Stolpman M., Speckman J., Allen K., and Beney J. The direct cost and incidence of systemic fungal infections. Value Health 5 (2002) 26-34
14. Health Care Utilization Project. Nationwide Inpatient Sample, Year 2003. Washington, DC: Department of Health and Human Services, U.S. Public Health Service, Agency for Healthcare Research and Quality; 2003.
15. Medicare Provider Analysis and Review. Fiscal year 2003. Baltimore, MD: CMS; 2003.
16. US Department of Commerce. United States Census Bureau On-line. Available at: www.census.gov (accessed April 2008).
17. Patterson T.F., Kirkpatrick W.R., White M., Hiemenz J.W., Wingard J.R., Dupont B., et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 79 (2000) 250-260
18. Alangaden G.J., Wahiduzzaman M., Chandrasekar P.H., and Bone Marrow Transplant Group. Aspergillosis: the most common community-acquired pneumonia with Gram-negative bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease. Clin Infect Dis 35 (2002) 659-664
19. Calvo V., Borro J.M., Morales P., Morcillo A., Vicente R., Tarrazona V., et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Chest 115 (1999) 1301-1304
20. Singh N., Avery R.K., Munoz P., Pruett T.L., Alexander B., Jacobs R., et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 36 (2003) 46-52
21. Wingard JR. Changing times: patient characteristics and fungal epidemiology. In: Fungal infections following BMT: re-examining current approaches. Presented at the Annual Meeting of the American Society for Blood and Marrow Transplantation, Keystone, Colorado, USA, 2003.
22. Kistemann T., Huneburg H., Exner M., Vacata V., and Engelhart S. Role of increased environmental Aspergillus exposure for patients with chronic obstructive pulmonary disease (COPD) treated with corticosteroids in an intensive care unit. Int J Hyg Environ Health 204 (2002) 347-351
23. Pelz R.K., Lipsett P.A., Swoboda S.M., Diener-West M., Powe N.R., Brower R.G., et al. Candida infections: outcome and attributable ICU costs in critically ill patients. J Intensive Care Med 15 (2000) 255-261
24. Vandewoude K., Blot S., Benoit D., Depuydt P., Vogelaers D., and Colardyn F. Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality. Acta Clin Belg 59 (2004) 251-257
25. Sharma S., Nadrous H.F., Peters S.G., Tefferi A., Litzow M.R., Aubry M.C., et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 128 (2005) 1385-1392
26. Jansen J.P., Kern W.V., Cornely O.A., Karthaus M., Ruhnke M., Ullmann A.J., et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 9 (2006) 12-23